Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects
Reviews in Cardiovascular Medicine · 23.12.2025 · 26 (12)
DOI: 10.31083/rcm45083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 23.12.2025. Verfasst von Kejian Gong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Hospital of Jilin University, 130021 Changchun, Jilin, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, creating an urgent demand for small-diameter vascular substitutes with durable long-term patency. Large-caliber synthetic grafts, such as polyethylene terephthalate (PET) and ePTFE, are well established in clinical practice; however, these synthetic grafts fail in small-diameter applications due to thrombosis and intimal hyperplasia. Moreover, autologous grafts are constrained by limited availability and variable quality. Recently, synthetic degradable polymers (e.g., polycaprolactone (PCL), poly(lactic-co-glycolic acid) (PLGA)), and extracellular matrix-derived natural materials (collagen, gelatin, silk fibroin, bacterial cellulose) have drawn increasing attention, as each offers distinct advantages and limitations in terms of mechanics, biocompatibility, and degradation behavior. Meanwhile, emerging fabrication technologies, including electrospinning, thermally induced phase separation, microfluidic spinning, and three-dimensional printing, are advancing the structural biomimicry and functional optimization of artificial vascular grafts. Thus, building on these developments, this review further examines the design strategies of tissue-engineered vascular grafts (TEVGs), focusing on cell sourcing, in vitro and in situ endothelialization, antithrombotic modification, and the prevention of intimal hyperplasia, while also summarizing outcomes from preclinical models and early clinical trials. Despite promising progress, the widespread clinical translation of TEVGs remains limited by prolonged manufacturing cycles, high costs, and insufficient long-term patency. Hence, future efforts toward standardized cell sources, integrated structure, function design, and multicenter clinical validation are critical to the development of next-generation vascular grafts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Hospital of Jilin University, 130021 Changchun, Jilin, China.
ORCID-Profile: Kejian Gong
Zitieren
APA
Gong, K., Wei, S., Zhang, X., & Liu, W. (2025). Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects. Reviews in Cardiovascular Medicine, 26(12). https://doi.org/10.31083/rcm45083
Vancouver
Gong K, Wei S, Zhang X, Liu W. Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects. Reviews in Cardiovascular Medicine. 2025;26(12). doi:10.31083/rcm45083
BibTeX
@article{Gong2025,
author = {Gong, Kejian and Wei, Shixiong and Zhang, Xinyun and Liu, Wei},
title = {Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects},
journal = {Reviews in Cardiovascular Medicine},
year = {2025},
volume = {26},
number = {12},
doi = {10.31083/rcm45083}
}
EUVIMED